Clinical Trials Directory

Trials / Completed

CompletedNCT03392051

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Clopidogrel In Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Akcea Therapeutics · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel

Conditions

Interventions

TypeNameDescription
DRUGISIS 681257Xmg dose administered as a subcutaneous injection
DRUGClopidogrel75mg tablet administered orally

Timeline

Start date
2017-12-28
Primary completion
2018-03-18
Completion
2018-03-18
First posted
2018-01-05
Last updated
2018-04-05

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03392051. Inclusion in this directory is not an endorsement.

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel (NCT03392051) · Clinical Trials Directory